HK1143551A1 - Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin - Google Patents
Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatinInfo
- Publication number
- HK1143551A1 HK1143551A1 HK10110187.0A HK10110187A HK1143551A1 HK 1143551 A1 HK1143551 A1 HK 1143551A1 HK 10110187 A HK10110187 A HK 10110187A HK 1143551 A1 HK1143551 A1 HK 1143551A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- complexes
- carboplatin
- phosphaplatins
- platinum
- fas
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 229960004562 carboplatin Drugs 0.000 title abstract 3
- 190000008236 carboplatin Chemical compound 0.000 title abstract 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 4
- 229910052697 platinum Inorganic materials 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 108091023040 Transcription factor Proteins 0.000 abstract 1
- 102000040945 Transcription factor Human genes 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 abstract 1
- 230000000861 pro-apoptotic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95412607P | 2007-08-06 | 2007-08-06 | |
| US97392607P | 2007-09-20 | 2007-09-20 | |
| PCT/US2008/072398 WO2009021082A2 (en) | 2007-08-06 | 2008-08-06 | Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1143551A1 true HK1143551A1 (en) | 2011-01-07 |
Family
ID=40342030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK10110187.0A HK1143551A1 (en) | 2007-08-06 | 2010-10-29 | Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US7700649B2 (pl) |
| EP (2) | EP2668949A1 (pl) |
| JP (2) | JP5385274B2 (pl) |
| CN (1) | CN101801369B (pl) |
| CY (1) | CY1115504T1 (pl) |
| DK (1) | DK2173337T3 (pl) |
| ES (1) | ES2495743T3 (pl) |
| HK (1) | HK1143551A1 (pl) |
| HR (1) | HRP20140808T1 (pl) |
| PL (1) | PL2173337T3 (pl) |
| PT (1) | PT2173337E (pl) |
| SI (1) | SI2173337T1 (pl) |
| WO (2) | WO2009021082A2 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2173337E (pt) | 2007-08-06 | 2014-09-03 | Univ Ohio | Fosfoplatinas e a sua utilização no tratamento de cancros resistentes à cisplantina e carboplatina |
| AP3480A (en) * | 2010-06-04 | 2015-12-31 | Univ Ohio | Phosphaplatins and their use for treatment of cancers |
| WO2012096722A1 (en) | 2011-01-12 | 2012-07-19 | Ohio University | Phosphaplatins having anti-angiogenic, anti-metastatic, and pro-apoptotic properties and uses thereof |
| MX354678B (es) | 2011-07-08 | 2018-03-15 | Dow Global Technologies Llc | Composicion de mezcla de polietileno adecuada para pelicula soplada, metodo para producir la misma y peliculas hechas a partir de la misma. |
| CN104010508B (zh) * | 2011-10-05 | 2017-03-15 | 理辛德拉·N·博斯 | 用于大规模制备磷铂类抗肿瘤剂的高效方法 |
| MX357865B (es) | 2011-10-05 | 2018-07-25 | N Bose Rathindra | Procedimientos eficientes para preparación a gran escala de agentes antitumorales de fosfaplatinos. |
| JP6255346B2 (ja) | 2011-10-20 | 2017-12-27 | ネリウム バイオテクノロジー，インコーポレーテッド | 癌治療のための治療用組合せ |
| PL3202769T3 (pl) | 2012-05-24 | 2020-03-31 | Phosplatin Therapeutics Llc | Sposoby oczyszczania związków fosfaplatyny |
| US9333211B2 (en) * | 2013-02-22 | 2016-05-10 | University Of Houston System | Phosphaplatin mediated modulation of pigment epithelial derived factor and uses thereof |
| WO2015127037A1 (en) * | 2014-02-19 | 2015-08-27 | University Of Houston System | Compositions and methods for the treatment of neurodegenerative diseases |
| CA2950305C (en) | 2014-06-11 | 2023-03-14 | Board Of Regents, The University Of Texas System | Texaphyrin-pt(iv) conjugates and compositions for use in overcoming platinum resistance |
| WO2017116356A1 (en) | 2015-12-30 | 2017-07-06 | Atilim Universitesi | Dna targeted mono and heterodinuclear complexes |
| JP7023968B2 (ja) * | 2017-01-06 | 2022-02-22 | フォスプラティン・セラピューティクス・インコーポレーテッド | 骨がんまたは血液がんの治療のための治療薬としてのホスファプラチン化合物 |
| CN111328330B (zh) * | 2017-09-08 | 2024-03-08 | 普罗蒙托里治疗有限公司 | 作为免疫调节剂的磷铂化合物及其治疗用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4234500A (en) * | 1979-03-07 | 1980-11-18 | Engelhard Minerals & Chemicals Corporation | Ethylenediamine platinum(II) and 1,2-diamino-cyclohexane platinum(II) pyrophosphate complexes |
| US4291027A (en) | 1979-03-07 | 1981-09-22 | Engelhard Minerals & Chemicals Corp. | Method for treating tumors with ethylenediamine platinum (II) and 1,2-diaminocyclohexane-platinum (II) pyrophosphate complexes |
| CA2017739A1 (en) * | 1989-07-18 | 1991-01-18 | Leslie S. Hollis | Cis-diamineplatinum complexes with methanediphosphonate and substituted methanediphosphonate ligands as antitumor agents |
| JP4463274B2 (ja) | 2003-06-27 | 2010-05-19 | 明 小谷 | ビスホスホネート錯体 |
| WO2009008345A1 (ja) * | 2007-07-06 | 2009-01-15 | Tmrc Co., Ltd. | 金属錯体化合物、これを有効成分とする癌治療剤組成物および該金属錯体化合物用の中間体 |
| PT2173337E (pt) * | 2007-08-06 | 2014-09-03 | Univ Ohio | Fosfoplatinas e a sua utilização no tratamento de cancros resistentes à cisplantina e carboplatina |
-
2008
- 2008-08-06 PT PT87973202T patent/PT2173337E/pt unknown
- 2008-08-06 US US12/187,376 patent/US7700649B2/en active Active
- 2008-08-06 SI SI200831280T patent/SI2173337T1/sl unknown
- 2008-08-06 ES ES08797320.2T patent/ES2495743T3/es active Active
- 2008-08-06 EP EP13182512.7A patent/EP2668949A1/en not_active Withdrawn
- 2008-08-06 EP EP08797320.2A patent/EP2173337B1/en active Active
- 2008-08-06 PL PL08797320T patent/PL2173337T3/pl unknown
- 2008-08-06 WO PCT/US2008/072398 patent/WO2009021082A2/en active Application Filing
- 2008-08-06 CN CN2008801015774A patent/CN101801369B/zh active Active
- 2008-08-06 DK DK08797320.2T patent/DK2173337T3/da active
- 2008-08-06 WO PCT/US2008/072397 patent/WO2009021081A2/en not_active Application Discontinuation
- 2008-08-06 JP JP2010520294A patent/JP5385274B2/ja active Active
-
2010
- 2010-03-11 US US12/722,189 patent/US8034964B2/en active Active
- 2010-10-29 HK HK10110187.0A patent/HK1143551A1/xx unknown
-
2011
- 2011-08-30 US US13/221,458 patent/US8445710B2/en active Active
-
2013
- 2013-03-15 US US13/842,885 patent/US8653132B2/en active Active
- 2013-06-07 JP JP2013120309A patent/JP5647300B2/ja active Active
-
2014
- 2014-08-27 CY CY20141100686T patent/CY1115504T1/el unknown
- 2014-08-27 HR HRP20140808AT patent/HRP20140808T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20130237503A1 (en) | 2013-09-12 |
| PL2173337T3 (pl) | 2014-11-28 |
| PT2173337E (pt) | 2014-09-03 |
| US8445710B2 (en) | 2013-05-21 |
| US20090042838A1 (en) | 2009-02-12 |
| JP5647300B2 (ja) | 2014-12-24 |
| US20110313182A1 (en) | 2011-12-22 |
| CN101801369A (zh) | 2010-08-11 |
| US8653132B2 (en) | 2014-02-18 |
| CN101801369B (zh) | 2012-09-19 |
| SI2173337T1 (sl) | 2014-10-30 |
| WO2009021081A2 (en) | 2009-02-12 |
| WO2009021081A3 (en) | 2009-05-07 |
| WO2009021082A3 (en) | 2009-04-23 |
| US20100233293A1 (en) | 2010-09-16 |
| EP2173337A2 (en) | 2010-04-14 |
| CY1115504T1 (el) | 2017-01-04 |
| JP2013227218A (ja) | 2013-11-07 |
| EP2173337A4 (en) | 2010-10-27 |
| DK2173337T3 (da) | 2014-09-15 |
| EP2668949A1 (en) | 2013-12-04 |
| JP2010535803A (ja) | 2010-11-25 |
| WO2009021082A2 (en) | 2009-02-12 |
| ES2495743T3 (es) | 2014-09-17 |
| US8034964B2 (en) | 2011-10-11 |
| HRP20140808T1 (hr) | 2014-10-24 |
| US7700649B2 (en) | 2010-04-20 |
| JP5385274B2 (ja) | 2014-01-08 |
| EP2173337B1 (en) | 2014-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1143551A1 (en) | Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin | |
| Brabec et al. | Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor drugs | |
| Wang et al. | Emerging platinum (IV) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment | |
| Zhou et al. | Photothermally triggered copper payload release for cuproptosis‐promoted cancer synergistic therapy | |
| Farrell | Multi-platinum anti-cancer agents. Substitution-inert compounds for tumor selectivity and new targets | |
| Reedijk | Platinum anticancer coordination compounds: study of DNA binding inspires new drug design | |
| Xiao et al. | A dual-targeting hybrid platinum (IV) prodrug for enhancing efficacy | |
| NZ628423A (en) | Methods of treating cancer | |
| Tabassum et al. | Synthesis and characterization of Cu (II)-based anticancer chemotherapeutic agent targeting topoisomerase Iα: In vitro DNA binding, pBR322 cleavage, molecular docking studies and cytotoxicity against human cancer cell lines | |
| WO2007098611A8 (en) | Compositions for treatment of cancer | |
| BR112015015319A2 (pt) | composições de nanopartícula de albumina e paclitaxel | |
| EP2796554A3 (en) | Compositions for use in treating BCL2-associated cancers | |
| WO2010132879A3 (en) | Multicomponent degradable cationic polymers | |
| WO2005083107A3 (en) | Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents | |
| Chin et al. | Synthesis, characterization and biological properties of cobalt (II) complexes of 1, 10-phenanthroline and maltol | |
| MX2009008281A (es) | Materiales de ion metalico de poli-oxo-hidroxi modificados con ligando, sus usos y procesos para su preparacion. | |
| Ramos-Lima et al. | Structural characterization, DNA interactions, and cytotoxicity of new transplatin analogues containing one aliphatic and one planar heterocyclic amine ligand | |
| Jayaramudu et al. | Green synthesis of tea Ag nanocomposite hydrogels via mint leaf extraction for effective antibacterial activity | |
| Yu et al. | Orthogonal γPNA dimerization domains empower DNA binders with cooperativity and versatility mimicking that of transcription factor pairs | |
| MX2021008261A (es) | Agentes de rnai para inhibir la expresion de hif-2 a (epas1), composiciones de estos y metodos de uso. | |
| Leung et al. | Epigenetic modulation by inorganic metal complexes | |
| Bostancıoğlu et al. | Studies on the cytotoxic, apoptotic and antitumoral effects of Au (III) and Pt (II) complexes of 1, 10-phenanthroline on V79 379A and A549 cell lines | |
| WO2007089161A3 (en) | DOUBLE HELICAL OLIGONUCLEOTIDES INTERFERING WITH mRNA USED AS EFFECTIVE ANTICANCER AGENT | |
| Orshiso et al. | Biosynthesis of Artemisia abyssinica leaf extract-mediated bimetallic ZnO–CuO nanoparticles: antioxidant, anticancer, and molecular docking studies | |
| WO2015081117A3 (en) | Therapeutic metal complexes |